The role of tramadol in current treatment strategies for musculoskeletal pain

Stephan A Schug
Pharmacology and Anaesthesiology Unit, School of Medicine and Pharmacology, University of Western Australia and Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, Western Australia

Abstract: Non-selective and cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) have been the mainstay of treatment for musculoskeletal pain of moderate intensity. However, in addition to gastrointestinal and renal toxicity, an increased cardiovascular risk may be a class effect for all NSAIDs. Despite these safety risks and the acknowledged ceiling effect of NSAIDs, many doctors still use them to treat moderate, mostly musculoskeletal pain. Recent guidelines for treating osteoarthritis and low back pain, issued by numerous professional medical societies, recommend NSAIDs and COX-2 inhibitors only in strictly defined circumstances, at the lowest effective dose and for the shortest possible period of time. These recent guidelines bring more focus to the usage of paracetamol and opioids. But opioids still remain under-utilized, although they are effective with minimal organ toxicity. In this setting, the atypical, centrally acting analgesic tramadol offers important benefits. Its multi-modal effect results from a dual mode of action, ie, opioid and monoaminergic mechanisms, with efficacy in both nociceptive and neuropathic pain. Moreover, fewer instances of side effects such as constipation, respiratory depression, and sedation occur than with traditional opioids, and tramadol has been prescribed for 30 years for a broad range of indications. Tramadol is now regarded as the first-line analgesic for many musculoskeletal indications. In conclusion, it is recommended to better implement the more recent guidelines focusing on pain management and consider the role of tramadol in musculoskeletal pain treatment strategies.

Keywords: musculoskeletal pain, osteoarthritis, chronic low back pain, opioids, NSAIDs, coxibs, tramadol, multi-modal

Introduction
The focus of this article is the current treatment of musculoskeletal pain – a therapeutic area that has seen many changes over the past few years. In 2002, American Pain Society guidelines for the management of osteoarthritis recommended cyclooxygenase-2 (COX-2) selective inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) (Simon et al 2002). However, the discovery that rofecoxib was linked to an increased incidence of myocardial infarction and stroke led to dramatic changes (Graham 2006). At first it was thought that increased cardiovascular risk might be a class effect of COX-2 inhibitors, but it is now understood that the problem extends to the non-selective NSAIDs (Graham et al 2005; Lee et al 2007). The US Food and Drug Administration (FDA) has clearly stated that a greater risk of cardiovascular events may be a class effect for all NSAIDs (FDA 2005). Although long-term clinical trials have not been conducted for most NSAIDs, the FDA concludes from the available data that their use could increase cardiovascular risk. Moreover, the gastric and renal toxicity associated with these agents is well established (Whelton 2000; Dieppe et al 2004). This paper reviews the recent guidelines for musculoskeletal pain with an emphasis on the role of an atypical opioid, tramadol, as an option.
Current guidelines

Recently, there has been a widespread re-examination of the management of musculoskeletal pain. For example, the Canadian Consensus Conference suggests that NSAIDs should be used with caution in elderly patients, who are at greatest risk of gastrointestinal, renal, and cardiovascular side effects (Tannenbaum et al 2006). This Conference also suggests that elderly patients with osteoarthritis or rheumatoid arthritis should be treated in the context of a multi-faceted treatment plan that aims to preserve function and independence and improve quality of life. This is a good and worthwhile concept, but it is necessary to define exactly how it can be achieved.

The European League Against Rheumatism (EULAR) has just published guidelines for the management of hip osteoarthritis (Zhang et al 2005). Interestingly, these state that opioid analgesics are useful alternatives in patients in whom NSAIDs – including COX-2 selective inhibitors – are contra-indicated, ineffective, and/or poorly tolerated. Nearly every set of guidelines that has appeared over the past 2 or 3 years recognizes that paracetamol and opioids have a more significant role to play in the management of chronic pain.

The European Guidelines for the Management of Chronic Non-Specific Low Back Pain (Airaksinen et al 2006) conclude that there is strong evidence that weak opioids relieve pain and disability in the short term in chronic low back pain patients. Notably, this is “level A” evidence comprising robust data. There is a clear suggestion that clinicians should decrease their use of organ-toxic NSAIDs and COX-2 inhibitors, and possibly increase the prescription of opioids.

The American Geriatrics Society Panel (AGS) on Persistent Pain in Older Persons now considers that for many older patients, chronic opioid therapy may have fewer life-threatening risks than long-term daily use of NSAIDs (AGS 2002). Comparing the organ toxicity of opioids and NSAIDs, this is clearly the case.

Choice of opioid

Thus guidelines produced over the past 4 years have shifted their emphasis from NSAIDs and COX-2 inhibitors to opioids, which clearly makes sense in the context of musculoskeletal pain. However, strong opioids are not always required. In this setting it is interesting to consider a drug that is not a monomodal opioid – tramadol. A better description of this agent is “a atypical centrally acting analgesic”. In the central nervous system (CNS), specifically in the dorsal horn of the spinal cord, tramadol has a number of effects, as illustrated in Figure 1. Where the first order neuron transmits a pain impulse to the second order neuron, which in turn relays the information to the brain, tramadol binds to some extent to the µ-opioid receptor (its M1 metabolite does so to a greater extent) (Grond and Sablotzki 2004); this produces some of its analgesic effect and explains why, model dependent, around 40% of tramadol analgesia can be reversed by opioid antagonists (Raffa et al 1992). In addition, the descending pathways responsible for pain relief rely on monoaminergic transmission, primarily via noradrenaline and serotonin. Here, tramadol binds to the descending pathway neurons, inhibiting the re-uptake of noradrenaline and serotonin, and accounting for the remaining analgesic properties (Desmeules et al 1996). Thus tramadol produces a multi-modal effect with its dual mechanism of action (Raffa and Friderichs 1996).

Traditional opioids produce analgesia but also cause constipation, respiratory depression, and sedation, as well as having a significant abuse potential (Vickers et al 1992; Grond et al 2001; Atluri et al 2003; Cicero et al 2004). It has been clearly demonstrated that the combined opioid and monoaminergic mechanisms of tramadol can mitigate these adverse effects (Richter et al 1985; Preston et al 1991; Epstein et al 2006). At the same time efficacy can be increased, particularly in patients suffering from neuropathic pain, where the enhancement of monoaminergic transmission is beneficial (Harati et al 1998; Sindrup et al 1999; Christoph et al 2007). Other side effects – dizziness, nausea, vomiting and sweating – remain at a similar level to traditional opioids (Allan et al 2001; Grond et al 2001). These differences are summarized in Table 1.

The efficacy and safety of tramadol in patients with musculoskeletal pain are both very well documented (see Table 2), and these have had an impact on treatment. A number of international guidelines now specifically recommend tramadol – not just weak opioids. The American Pain Society suggests that tramadol can be used alone, or in combination with paracetamol or NSAIDs, for therapy at any stage during the treatment of a patient with osteoarthritis. The American College of Rheumatology states that the efficacy of tramadol has been found to be comparable with that of ibuprofen in patients with hip and knee osteoarthritis, and has proven useful as adjunctive therapy in patients whose symptoms are inadequately controlled by NSAIDs (Dalgin et al 1997; Roth 1998; Altman et al 2000). The clear implication is that tramadol may be used instead of an NSAID, for example in patients with cardiac or renal complications (Whelton 2000; Aronow 2003). If a patient is already receiving an NSAID it can be combined with tramadol in a multi-modal analgesic approach thereby permitting dose
Tramadol for musculoskeletal pain

reduction of the NSAID (Schnitzer et al 1999). For patients with chronic low back pain, the previously quoted European Guidelines explicitly recommend the use of “weak opioids (eg, tramadol)” in patients with non-specific chronic low back pain who do not respond to other treatment modalities (Airaksinen et al 2006).

Even in conditions where central sensitization is now thought to play an important role, there is support for the use of tramadol. For example, the Veterans Health Administration of the US Department of Defence considers tramadol to be a therapeutic intervention with some benefits for sufferers from fibromyalgia (Buckhardt et al 2005). In the long-term care of the elderly, the American Medical Directors Association says that tramadol is a first line pharmacological treatment for chronic pain, together with paracetamol, NSAIDs, and COX-2 inhibitors (AMDA 2003).

The working group on pain management

It is apparent that revised guidelines for pain management are needed, and that these will encourage greater prescription of opioids and reduced use of NSAIDs and COX-2 inhibitors, as well as specifically recommending tramadol. There is a Working Group on Pain Management which regularly publishes its findings, including guidelines (Schnitzer 2006) (on the Internet at www.painworkinggroup.org). Its recommendations today differ significantly from those issued by others before 2004.

Osteoarthritis patients without particular risk factors should receive background analgesia with up to 4 g/day of paracetamol. For a short-term flare, NSAIDs or the immediate-release paracetamol–tramadol fixed combination tablet should be administered. If this does not adequately control the pain then immediate release tramadol can be administered. An immediate-release strong opioid can be considered if the patient still experiences insufficient pain relief. For long-term pain management, NSAIDs are not recommended. The regimen is similar to that for short-term treatment but there are advantages to prescribing sustained-release tramadol formulations. These treatment regimens are summarized in Figure 2.

In elderly patients with low back pain who have no particular risk factors and require long term pain management,
the working group recommends the use of a weak opioid plus paracetamol, or tramadol monotherapy (see Figure 3). NSAIDs and COX-2 inhibitors can be prescribed for young healthy adults without risk factors, but even the FDA and the European Medicines Agency (EMEA 2005) now state that the smallest possible dose should be used for the shortest possible time. So the paracetamol–tramadol fixed combination tablet or tramadol sustained release may be preferred. Thus the achievement of pain management goals such as improved functioning, return to work, and a better quality of life is based largely on paracetamol and tramadol.

There is a large body of high quality evidence for using tramadol as suggested by the working group, particularly in neuropathic pain. Low back pain often has a neuropathic component, which plays a major role in the condition of patients referred to chronic pain clinics. One recent large scale study found that in an unselected cohort of chronic low back pain patients, 37% had predominantly neuropathic pain (Freyhnagen et al 2006). This is also the pain component that is most difficult to treat in the general practice setting.

Tramadol is increasingly gaining acceptance as it is effective against both nociceptive and neuropathic pain. There have now been a considerable number of randomized, controlled trials, and a Cochrane review, that show a high efficacy of tramadol in neuropathic pain (Dühmke et al 2004);

Table 1 Effects of traditional opioids in comparison with tramadol

| Analgesic efficacy          | Tramadol in comparison with typical strong opioids |
|-----------------------------|----------------------------------------------------|
| – in nociceptive pain       | effective                                          |
| – in neuropathic pain       | first line option                                  |
| – in mixed pain             | effective                                          |
| Abuse potential             | less                                               |
| Side effects                |                                                    |
| – respiratory depression    | less                                               |
| – constipation              | less                                               |
| – sedation                  | less                                               |
| – dizziness                 | equal                                              |
| – nausea                    | equal                                              |
| – vomiting                  | equal                                              |
| – sweating                  | equal                                              |

Table 2 Controlled trials of oral tramadol in patients with chronic musculoskeletal pain

| Study                  | Type of pain | Study design | N  | Duration | Analgesic drug               | Dosage (mg/day) | Analgesic efficacy | Adverse events |
|------------------------|--------------|--------------|----|----------|------------------------------|-----------------|-------------------|-----------------|
| Adler et al 2002       | Osteoarthritis | db           | 279| 1 mo     | SR tramadol/IR tramadol      | 150–400         | SR-T = IR-T       | SR-T = IR-T     |
| Bird et al 1995        | Osteoarthritis | db, co       | 40 | 2 × 2 wk | IR tramadol                  | 200             | T > PE            | T < PE          |
| Gorol 1983             | Chronic      | db           | 94 | 1 wk     | IR tramadol/Tilidine/naloxone| prn             | T > Ti/N          | NR              |
| Jensen and Ginsberg 1994| Osteoarthritis | db, co       | 264| 2 wk     | IR tramadol                  | 300             | T > D             | T > D           |
| Pavelka et al 1998     | Osteoarthritis | db           | 60 | 2 × 4 wk | IR tramadol                  | 164             | T = DI            | T = DI          |
| Rauck et al 1994       | Chronic      | db           | 990| 4 wk     | IR tramadol/Diclofenac       | 244             |                   |                 |
| Schnitzer et al 2000   | Low back     | db           | 254| 4 wk     | IR tramadol                  | 200–400         | T > PL            |                 |
| Silverfield et al 2002 | Osteoarthritis | db           | 308| 10 d     | IR tramadol/Placebo          | 150–300/1300–2600| T/P > PL         | T/P > PL        |
| Sorge and Stadler 1997 | Low back     | db           | 205| 3 wk     | SR tramadol                  | 200             | SR-T = IR-T       | SR-T = IR-T     |
| Wilder-Smith et al 2001| Osteoarthritis | db           | 60 | 1 mo     | SR tramadol                  | 200             | T > DC            |                 |

Abbreviations: C, codeine; co, crossover; d, days; D, dextropropoxyphene; db, double-blind; DC, dihydrocodeine; DI, diclofenac; IR, immediate release; mo, months; N, naloxone; NR, not reported; P, paracetamol; PE, pentazocine; PL, placebo; prn, as needed; SR, sustained-release; T, tramadol; Ti, tilidine; wk, weeks; > indicates superior to; = indicates equivalent to; < indicates inferior to.
Tramadol for musculoskeletal pain

Moderate to Severe OA Pain: Systemic Analgesia
Patients without Particular Risk Factors

Paracetamol up to 4 g/day
+/- glucosamine
If insufficient

| Pain Intensity | Short-term / flare | Long-term |
|----------------|-------------------|-----------|
| Moderate       | NSAIDs            | Paracetamol/tramadol |
|                | Weak opioid comb. |           |
|                | e.g. paracetamol/tramadol |   |
|                | Tramadol IR       | Tramadol SR |
|                | Strong opioids IR | Strong opioids SR |

Figure 2 Recommendations of the working group on pain management for patients with osteoarthritis.

the number needed to treat (NNT) compared with placebo to achieve at least 50% pain relief was 3.5 with a number needed to harm (NNH) of 7.7. Based on these favorable numbers, in the latest evidence-based algorithms for treating neuropathic pain, tramadol is very high in the sequence of drugs that should be used (Dworkin et al 2003; Finnerup et al 2005).

Conclusion – the need for change
Many doctors still use NSAIDs and COX-2 inhibitors to treat musculoskeletal pain, despite the safety risks and the fact that these agents have a ceiling effect, so that continuing to increase the dose only results in a greater incidence of adverse events. Also, the inflammatory component of osteoarthritis pain is minimal (Backonja 2003) – perhaps osteoarthrosis would be a more accurate term, so an anti-inflammatory drug is not needed in these patients, and NSAIDs carry the risk of organ toxicity (Singh 2000; Lanas et al 2003; Dieppe et al 2004; Laporte et al 2004; Graham et al 2005). This was previously believed to be limited to the kidney and stomach but is now known to extend to the heart and cardiovascular system (Davies et al 2006). Opioids are currently under-utilized, although they are known to be effective and have minimum organ toxicity – possibly none in most settings – even in long-term use (Brown and Stinson 2004; Raffa 2006). This might be of particular importance in the elderly, as they exhibit commonly already impaired or reduced organ function (Auret and Schug 2005). Many guidelines have changed in the last 4 years, but have not yet been implemented in routine clinical practice.

Tramadol is now specifically recommended in musculoskeletal pain guidelines and neuropathic pain guidelines, because of its efficacy, safety, and tolerability (Dworkin et al 2003; Dühmke et al 2004; Finnerup et al 2005). Clearly there is no major organ toxicity (Shipton 2000; Raffa 2006), and its use necessarily implies an NSAID-sparing effect (Schnitzer et al 1999). The improved side effect profile over traditional opioids is particularly marked in the case of constipation, which is usually the biggest problem with opioid use in the elderly. Finally, tramadol has been on the market for 30 years and clinical experience now extends to more than 5 billion patient treatment days, so the data underlying the latest guidelines are extremely robust (IMS Health Inc. 1994–2005).
Low Back Pain: Systemic Analgesia
Patients without Particular Risk Factors

| Pain Intensity | Elderly | Young/healthy |
|---------------|---------|---------------|
| Moderate      | - Weak opioid combinations, e.g. paracetamol/tramadol* |
|               | - Tramadol SR |
|               | - Strong opioids |
| Severe        | - Coxibs/NSAIDs (low dose) +/- paracetamol/tramadol* (NSAID-sparing) |
|               | - Tramadol SR* |
|               | - Strong opioids |

* Tramadol is efficacious for both nociceptive and neuropathic pain
** In neuropathic pain consider co-analgesics

**Figure 3** Recommendations of the working group on pain management for patients with low back pain.

References
Adler L, McDonald C, O’Brien C, et al 2002. A comparison of once-daily tramadol with normal-release tramadol in the treatment of pain in osteoarthritis. *J Rheumatol*, 29:2196–9.
Airakiesen O, Brox JI, Cedraschi C, et al 2006. European guidelines for the management of chronic non-specific low back pain. *Eur Spine J*, 15(Suppl 2):S192–S300.
Allan L, Hays H, Jensen NH, et al 2001. Randomised crossover trial of transdermal fentanyl and sustained-release oral morphine for treating chronic non-cancer pain. *BMJ*, 322:1154–61.
Altman RD, et al 2000. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. *Arthritis Rheum*, 43:1905–15.
[AMDA] American Medical Directors Association. 2003. Pain management in the long-term care setting. Clinical practice guideline. URL: http://www.amda.com/tools/cpg/chronicpain.cfm.
[AGS] American Geriatrics Society Panel on Persistent Pain in Older Persons. 2002. The management of persistent pain in older persons. *J Am Geriatr Soc*, 50(6 Suppl):S205–S24.
Aronow WS. 2003. Treatment of heart failure in older persons: dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. *Congest Heart Fail*, 9:142–7.
Afturi S, Boswell MV, Hansen HC, et al 2003. Guidelines for the use of controlled substances in the management of chronic pain. *Pain Physician*, 6:233–57.
Auret K, Schug SA. 2005. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. *Drugs Aging*, 22:641–54.
Backonja M-M. 2003. Defining neuropathic pain. *Anesth Analg*, 97:785–90.
Bird HA, Hill J, Stratford M. 1995. A double-blind cross-over study comparing the analgesic efficacy of tramadol with pentazocine in patients with arthritis. *J Drug Dev Clin Pract*, 7:81–8.
Brown SC, Stinson J. 2004. Treatment of pediatric chronic pain with tramadol hydrochloride: siblings with Ehlers-Danlos syndrome – Hypermobility type. *Pain Res Manage*, 9:209–11.
Buckhard, CS, Goldenberg D, Crofford L, et al 2005. Guideline for the management of fibromyalgia syndrome in adults and children. Glenview (IL): American Pain Society (APS), Christoph T, Kögler B, Strassburger W, et al 2007. Tramadol has a better potency ratio relative to morphine in neuropathic than nociceptive pain models. *Drugs in R&D*, 8:51–7.
Cicero TJ, Inciardi JA, Adams EA, et al 2005. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994–2004. *Pharmacoepidemiol Drug Saf*, 14:851–9.
Collart L, Luthy C, Dayer P. 1997. Complete inhibition of tramadol antinociceptive effect by naloxone in man. *Br J Clin Pharmacol*, 35:73.
Dalgin P. 1997. the TPS-OA Study Group. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis [abstract]. *Arthritis Rheum*, 40(Suppl 9):S86.
Davies NM, Reynolds JK, Undeberg MR, et al 2006. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. *Expert Rev Neurother*, 6:1643–55.
Desmeules JA, Piguet V, Collart L, et al 1996. Contribution of monoaminergic modulation to the analgesic effect of tramadol. *Br J Clin Pharmacol*, 41:7–12.
Diefte P, Bartlett C, Davey P, et al. 2004. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ, 329:31–4.

Dühnke RM, Cornblath DD, Hollingshead JRF. 2004. Tramadol for neuropathic pain. The Cochrane Database of Systematic Reviews 2004, Issue 2.

Dworkin RH, Backonja M, Rowbotham MC, et al. 2003. Advances in neuropathic pain: Diagnosis, mechanisms and treatment recommendations. Arch Neurol, 60:1524–34.

[EMEA] European Medicines Agency. 2005. URL: http://www.ema.eu.int/pdfs/human/press/pr/24732305en.pdf.

Epstein DH, Preston KL, Jasinski DR. 2006. Abuse liability, behavioural pharmacology, and physical dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biol Psychol, 73:90–9.

[FDA]. Food and Drug Administration. 2005. URL: http://www.fda.gov/cder/drug/infopage/COX2/NSAIDRxtemplate.pdf; http://www.fda.gov/cder/rug/infopage/cox2/COX2qa.htm

Finnerup NB, Otto M, McQuay HJ, et al. 2005. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain, 118:289–305.

Freynhagen R, Baron R, Gockel U, et al. 2006. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin, 22:1911–20.

Gorod D. 1993. Tropfenform eines stark wirksamen Analgetikums in der Doppelblindprüfung. Med Klin, 78:173–7.

Graham DJ. 2006. COX-2 Inhibitors, Other NSAIDs, and cardiovascular risk the seduction of common sense. JAMA, 296:1563–6.

Graham DY, Opekun AR, Willingham FF, et al. 2005. Visible Small-Intestinal Mucosal Injury in Chronic NSAID Users. Pain, 118:289–305.

Grond S, Meert TF, Noorduin H. 2001. Safety and tolerability of opioid analgesia: a comparable class profile? Pain Rev, 8:103–11.

Grond S, Sablotzki A. 2004. Clinical pharmacology of tramadol. Clin Pharmacokinet, 43:879–923.

Harati Y, Gooch G, Swenson M, et al. 2000. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications, 14:65–70.

IMS Health Inc., IMS Chemical Kilochem Profi le and IMS Midas, 1994–2005 and Defi ned Daily Dose of 300 mg tramadol according to WHO [online]. URL: http://www.who.cc/notcdd/indexdatabase.

Jensen EM, Ginsberg F. 1984. Tramadol versus dextropropoxyphene in the treatment of osteoarthritis. Drug Invest, 8:211–18.

Laporte J-R, Ibáñez L, Vidal X, et al. 2004. Upper gastrointestinal bleeding with non-aspirin cardiovascular drugs, analgesics and combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clin Ther, 24:282–97.

Lee TA, Bartle B, Weiss KB. 2007. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med, 120:98.e9–16.

Lanas A, Serrano P, Bajador E, et al. 2003. Risk of upper gastrointestinal bleeding with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol, 15:173–8.

Lee TA, Bartle B, Weiss KB. 2007. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med, 120:98.e9–16.

Lavoie S, Belanger S, Colombier S, et al. 2001. Safety and tolerability of tramadol 100 mg sustained-release tablets and tramadol 50 mg capsules for the treatment of chronic low back pain. Clin Drug Invest, 14:157–64.

Pavelka K, Pelisikova Z, Stelikova H. 1998. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Invest, 16:1–9.

Preston KL, Jasinski DR, Testa M. 1991. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend, 27:7–17.

Raffa R. 2006. Pharmacological aspects of successful long-term analgesia. Clin Rheumatol, 25(Suppl 1):9–15.

Raffa RB, Friderichs E. 1996. The basic science aspect of tramadol hydrochloride. Pain Rev, 3:249–71.

Raffa RB, Friderichs E, Reimann W, et al. 1992. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther, 260:275–85.

Rauck RL, Ruoff GE, McMillen JL. 1994. Comparison of tramadol and acetaminophen with codeine for long-term pain management in elderly patients. Curr Ther Res Clin Exp, 55:1417–31.

Richter W, Barth H, Flohé L, et al. 1985. Clinical investigation on the development of dependence during oral therapy with tramadol. Arzneimittelforschung, 35:1742–4.

Roth SH. 1998. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol, 25:1358–63.

Schnitzer TJ. 2006. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol, 25(Suppl 1):S22–S9.

Schnitzer TJ, Gray WL, Paster RZ, et al. 2000. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol, 27:772–8.

Sindrup SH, Andersen G, Madsen C, et al. 1999. Tramadol relieves pain and alldynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain, 83:85–90.

Singh G. 2000. Gastrointestinal Complications of Prescription and OTC Nonsteroidal Anti-Inflammatory Drugs: A View from the ARAMIS Database. Am J Therap, 7:115–21.

Tannenbaum H, Bombardier C, Davis P, et al. 2006. An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference Group. J Rheumatol, 33:140–57.

Vickers MD, O’Flaherty D, Szekely SM, et al. 1992. Tramadol: pain relief by antinociception and gastrointestinal effects. Pain, 50:152–61.

Whelton A. 2000. Renal and related cardiovascular effects of conventional and slow-release tramadol or dihydrocodeine in treatment of chronic low back pain. Curr Drug Invest, 4:157–64.

Wilders-Smith CH, Hill L, Spargo K, et al. 2001. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDs: a randomised study comparing analgesia, antinoceception and gastrointestinal effects. Pain, 91:23–31.

Zhang W, Doherty M, Arden N, et al. 2005. EULAR evidence-based recommendations for the management of hip osteoarthritis – report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 64:669–81.
